Pellat A, et al. - This study incorporated an investigation of the potential predictive biomarkers of sunitinib activity in patients with advanced grade 3 gastroenteropancreatic neuroendocrine neoplasms (GEPNEN-G3). Evidence of activity in patients with GEPNEN-G3 with an expected toxicity profile was illustrated via sunitinib. It was determined that in the well-differentiated tumours (NET-G3) and neuroendocrine carcinoma (NEC) groups, 4/6 and 11/20 patients were responders, respectively. A lower response to sunitinib was speculated through high p-AKT expression. Hence, researchers were able to detect a potential biomarker of resistance/sensitivity to sunitinib in aggressive GEPNEN-G3.